Clinical trial NCT00778089: Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing
Official title: Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hypersensitivity
Keywords: skin test
ArteFill
Skin test prior to administration of ArteFill® implant
Lead sponsor: Suneva Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2008-10-23
Enrollment: 498
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to assess the clinical utility of the ArteFill® pre-treatment Skin Test in predicting and preventing hypersensitivity reactions to treatment with ArteFill® implant

Detailed description: This is a single-center, open-label study in approximately 485 healthy male and female subjects to obtain 450 evaluable subjects. In this protocol, an ArteFill® Skin Test study will be conducted to evaluate the test's clinical utility to determine the incidence of positive skin reactions to ArteFill®. The results of this skin test study will determine if the risk of a hypersensitivity reaction against ArteFill® without a skin test is no greater than the published historical risk of a hypersensitivity reaction against a Zyderm or Zyplast treatment after a patient demonstrates a negative response to a single Zyderm skin test. Based on prior clinical experience with ArteFill® implant in commercial use outside the United States, it is anticipated that no reactions will be observed. As such, it may be suggested that there is no practical use of the ArteFill® Skin Test for screening patients, and therefore, the test may be eliminated as a requirement prior to treatment with the ArteFill® product as is the clinical practice outside the United States.

Eligibility criteria: Inclusion Criteria:

* Subjects 18 years of age or older, male or female.
* Subjects who are healthy and have normal skin on the volar surface of the forearm.
* Subjects willing and able to comply with the requirements of the study.
* Subjects willing and able to comply with the follow-up requirements.
* Subjects willing and able to give written and verbal informed consent.

Exclusion Criteria:

* Subjects who are pregnant, nursing or intend to become pregnant.
* Subjects who have had any form of collagen soft tissue treatment within the last 12 months.
* Subjects who were or are currently being treated with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids (including inhaled or insufflated) within the past 3 months.
* Subjects who were or are currently being treated with any topical OTC drug or prescription therapy on their arms (below the elbow) within the past 3 months.
* Subjects with a history indicative of abnormal immune function (e.g. auto- immune diseases, HIV, cancer, etc).
* Subjects with known lidocaine hypersensitivity.
* Subjects with known sensitivity to bovine collagen.
* Subjects who have a history of dietary beef allergy, undergoing desensitization to beef products or planning to undergo desensitization within the study evaluation period.
* Subjects with severe allergies manifested by a history of anaphylaxis.
* Subject is currently enrolled in an investigational drug or device study.
* Subject has received an investigational drug or an investigational device within 30 days prior to entering this study.
* Subject has any skin pathology or condition that could interfere with the evaluation of the treatment areas.

Primary outcomes:
measure: Safety will be assessed by determination of a positive hypersensitivity reaction to the skin test and collection of adverse events.
timeFrame: 60 days
Secondary outcomes:
measure: In addition to the primary outcome measure, to assist in assessing the etiology of the reaction, the immune response to the skin test in subjects with positive skin test will be evaluated by measuring serum antibody levels against bovine collagen.
timeFrame: 60 days
Other outcomes:
Locations:
city: Lynchburg
country: United States
facility: The Education & Research Foundation, Inc.
state: Virginia
Study officials:
affiliation: The Education & Research Foundation, Inc.
name: David C Wilson, M.D.
role: PRINCIPAL_INVESTIGATOR
References: